MASH: Survodutide improves Steatohepatitis and Fibrosis

被引：0
|
作者：
Krome, Susanne
机构：
来源：
ZEITSCHRIFT FUR GASTROENTEROLOGIE | 2025年 / 63卷 / 01期
关键词：
D O I：
10.1055/a-2392-2365
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) is associated with increased morbidity and mortality. GLP-1 receptor agonists have a positive effect, but have no direct influence on the liver because hepatocytes lack GLP-1 receptors. Unidual agonism with the combination of GLP-1 and glucagon receptor agonism is said to improve the results. Survodutide has this dual agonistic function and met the endpoints in a double-blind parallel group study.
引用
收藏
页码：20 / 20
页数：1
相关论文
共 50 条
  • [21] Aramchol improves hepatic fibrosis in MASH: Results of multimodality assessment using both conventional and digital pathology
    Ratziu, Vlad
    Yilmaz, Yusuf
    Lazas, Don
    Friedman, Scott L.
    Lackner, Caroline
    Behling, Cynthia
    Cummings, Oscar W.
    Chen, Li
    Petitjean, Matthieu
    Gilgun-Sherki, Yossi
    Gorfine, Tali
    Kadosh, Shaul
    Eyal, Eli
    Sanyal, Arun J.
    HEPATOLOGY, 2024,
  • [22] MASH RESOLUTION WITHOUT FIBROSIS WORSENING AFTER BARIATRIC SURGERY IMPROVES LONG- TERM SURVIVAL
    Lassailly, Guillaume
    Caiazzo, Robert
    Gnemmi, Viviane
    Verkindt, Helene
    Ntandja-Wandji, Line-Carolle
    Ningarhari, Massih
    Leteurtre, Emmanuelle
    Raverdy, Violetta
    Dharancy, Sebastien
    Louvet, Alexandre
    Pattou, Francois
    Mathurin, Philippe
    HEPATOLOGY, 2023, 78 : S1 - S1
  • [23] SOLUBLE SIGLEC-9 IMPROVES INTESTINAL BARRIER FUNCTION IN A MOUSE MODEL OF METABOLIC-DYSFUNCTION ASSOCIATED STEATOHEPATITIS ( MASH)
    Muto, Hisanori
    Mizuno, Fumitaka
    Yokoyama, Shinya
    Tanaka, Taku
    Yamamoto, Kenta
    Ito, Takanori
    Ishizu, Yoji
    Honda, Takashi
    Ishigami, Masatoshi
    HEPATOLOGY, 2024, 80 : S5 - S6
  • [24] Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)
    Do, Albert
    Zahrawi, Frhaan
    Mehal, Wajahat Z.
    NATURE REVIEWS DRUG DISCOVERY, 2025, 24 (03) : 171 - 189
  • [25] Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)
    Do, Albert
    Zahrawi, Frhaan
    Mehal, Wajahat Z.
    NATURE REVIEWS DRUG DISCOVERY, 2024,
  • [26] Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)
    Albert Do
    Frhaan Zahrawi
    Wajahat Z. Mehal
    Nature Reviews Drug Discovery, 2025, 24 (3) : 171 - 189
  • [27] Targeting PNPLA3 to Treat MASH and MASH Related Fibrosis and Cirrhosis
    Linden, Daniel
    Tesz, Gregory
    Loomba, Rohit
    LIVER INTERNATIONAL, 2025, 45 (04)
  • [28] Targeted interleukin-22 therapy improves glycemic control, steatohepatitis, and fibrosis in experimental models of metabolic dysfunction-associated steatohepatitis
    Sajiir, H.
    Keshvari, S.
    Wong, K. Y.
    Borg, D.
    Mueller, A.
    Moniruzzaman, M.
    Wang, R.
    Fotheringham, A.
    Schreiber, V.
    Sheng, Y.
    Lockett, J.
    Ramm, G.
    Macdonald, G.
    Prins, J. B.
    Mcguckin, M. A.
    Hasnain, S. Z.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2023, 38 : 37 - 37
  • [29] Weight reduction improves steatohepatitis in non alcoholic steatohepatitis
    Ahn, Sang Bong
    Lee, Ji Hyun
    Cho, Young Kwan
    Son, Byoung Kwan
    Kim, Seong Hwan
    Jo, Yun Ju
    Park, Young Sook
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2013, 28 : 185 - 185
  • [30] Orlistat Reverse Fatty Infiltration and Improves Hepatic Fibrosis in Obese Patients with Nonalcoholic Steatohepatitis (NASH)
    Osamah Hussein
    Masha Grosovski
    Sorina Schlesinger
    Sergio Szvalb
    Nimer Assy
    Digestive Diseases and Sciences, 2007, 52 : 2512 - 2519
12345